Go Pro
NASDAQ:POAI

Predictive Oncology (POAI) Stock Price, News & Analysis

Predictive Oncology logo
$8.38 -0.12 (-1.41%)
As of 07/31/2026

About Predictive Oncology Stock (NASDAQ:POAI)

Advanced

Key Stats

Today's Range
$7.80
$8.50
50-Day Range
$5.34
$9.54
52-Week Range
$0.71
$16.54
Volume
203,136 shs
Average Volume
473,545 shs
Market Capitalization
$28.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Predictive Oncology, Inc. is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells. This platform is complemented by proprietary data integration tools that correlate cellular phenotypes with genetic and molecular profiles. Predictive Oncology also provides custom assay development and contract research services to pharmaceutical and biotech partners seeking to validate drug mechanisms, optimize dosing regimens, or identify novel targets in oncology and related therapeutic areas.

Headquartered in St. James, New York, Predictive Oncology serves a global customer base that includes large pharmaceutical companies, emerging biotechs, and academic research institutions. The company began trading on the Nasdaq Capital Market under the ticker POAI in December 2020. Its leadership team brings together expertise in computational biology, oncology research, and data science, positioning Predictive Oncology at the intersection of cutting-edge technology and translational cancer research.

AI Generated. May Contain Errors.

Receive POAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

POAI Stock News Headlines

Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Predictive Oncology Regains Nasdaq Compliance
See More Headlines

POAI Stock Analysis - Frequently Asked Questions

Predictive Oncology's stock was trading at $7.15 on January 1st, 2026. Since then, POAI stock has increased by 17.2% and is now trading at $8.38.

Predictive Oncology Inc. (NASDAQ:POAI) announced its quarterly earnings results on Friday, November, 14th. The medical instruments supplier reported ($4.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by $3.17. The medical instruments supplier earned $0 million during the quarter, compared to the consensus estimate of $1.50 million. Predictive Oncology had a negative trailing twelve-month return on equity of 732.73% and a negative net margin of 5,065.23%.
Read the conference call transcript
.

Predictive Oncology shares reverse split on the morning of Tuesday, September 30th 2025.The 1-15 reverse split was announced on Thursday, September 25th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Predictive Oncology investors own include Ford Motor (F), Wells Fargo & Company (WFC), Zomedica (ZOM), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Bank of America (BAC) and Wayfair (W).

Company Calendar

Last Earnings
11/14/2025
Today
8/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
IT Services
Sub-Industry
Internet Services & Infrastructure
Current Symbol
NASDAQ:POAI
CIK
1446159
Fax
N/A
Employees
30
Year Founded
2002

Profitability

EPS (Trailing Twelve Months)
($13.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.66 million
Net Margins
-5,065.23%
Pretax Margin
-5,082.34%
Return on Equity
-732.73%
Return on Assets
-235.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.01
Quick Ratio
0.01

Sales & Book Value

Annual Sales
$1.66 million
Price / Sales
17.09
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.46) per share
Price / Book
-18.22

Miscellaneous

Outstanding Shares
3,394,000
Free Float
3,353,000
Market Cap
$28.44 million
Optionable
Not Optionable
Beta
1.35

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:POAI) was last updated on 8/1/2026 by MarketBeat.com Staff.
From Our Partners